Development
Pfizer Inc.
PFE
$23.35
$0.231.00%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 12/31/2023 | 10/01/2023 | 07/02/2023 | 04/02/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -85.65% | -56.79% | -26.73% | 16.36% | 42.74% |
| Total Depreciation and Amortization | -6.46% | -6.29% | 14.70% | 4.68% | -1.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -99.93% | 1.92% | 86.76% | 99.82% | 79.55% |
| Change in Net Operating Assets | 82.75% | -13.62% | -322.17% | -177.99% | -144.04% |
| Cash from Operations | -82.08% | -67.72% | -53.71% | -30.78% | -10.17% |
| Capital Expenditure | 4.30% | 5.65% | -29.23% | -33.29% | -19.37% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -88.85% | -169.83% | -169.83% | -169.43% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 27.86% | -49.63% | 54.02% | 166.65% | 152.68% |
| Cash from Investing | -110.14% | -90.41% | -16.23% | 35.57% | 30.00% |
| Total Debt Issued | 890.47% | 567.88% | 463.60% | 314.04% | 290.27% |
| Total Debt Repaid | 84.26% | 51.77% | -120.16% | -49.77% | -252.71% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | 100.00% | 100.00% | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 22.82% | 23.12% | -2.72% | -2.62% | -2.91% |
| Other Financing Activities | -77.61% | -304.26% | -415.64% | -315.08% | -2,193.75% |
| Cash from Financing | 301.19% | 247.21% | 260.13% | 18.84% | -51.12% |
| Foreign Exchange rate Adjustments | 95.15% | 80.12% | 19.85% | -176.67% | -179.66% |
| Miscellaneous Cash Flow Adjustments | -- | -300.00% | -200.00% | 100.00% | -- |
| Net Change in Cash | 226.20% | 295.54% | 247.22% | -141.25% | -1,052.83% |